Bone Graft Substitutes Patents: Who Leads, Where Gaps Are 2026
Bone graft substitute patents: mapping the leaders, the filing slowdown and the open claim space
Concentrated but not locked up. the top 5 assignees hold 20.6% of all 3,352 records in scope, and the top 10 hold 33.5% — leaving most of the field to a long tail of single- and low-volume filers. Annual filings ran from a peak of 132 in 2017 to 3 in 2026 (a partial year). The clearer signal sits in the last complete years: 2021 filings totalled 105, falling to 37 by 2024 — a 65% decline. Because publication typically lags filing by around 18 months, 2025 and 2026 counts are still incomplete and should not be read as confirmation that the decline continues at that pace.
- 1WARSAW ORTHOPEDIC INC6.0%
- 2ETEX CORP4.3%
- 3ADA FOUND3.6%
- 4OSSDSIGN3.5%
- 5GRAFTYS3.2%
See the full bone graft substitutes analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on bone graft substitute patents
Who are the leading patent holders in bone graft substitutes?
The assignee ranking in this dataset covers 100 companies by patent family count, with the leader holding 200 families against 106 for the fifth-ranked assignee and 69 for the tenth. Together the top 5 assignees account for 20.6% of the 3,352 records in scope, and the top 10 account for 33.5%. That leaves roughly two-thirds of filings spread across a long tail of smaller and single-filing entrants, so leadership in this field is concentrated but far from exclusive.
Is patent filing in bone graft substitutes increasing or decreasing?
Filing peaked in 2017 at 132 records and has since declined, falling from 105 in 2021 to 37 in 2024 — a 65% drop across those three complete filing years. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so the most recent years understate actual filing activity. Based on the complete-year data available, the trend through 2024 points to a cooling rather than an expanding field.
What technology areas dominate bone graft substitute patent claims?
Sterilising and disinfecting technology (IPC class A61L) appears on 66.9% of the 3,352 records, making it the single most common claim area, ahead of medicinal preparations (A61K, 37.0%) and implants/prostheses (A61F, 31.7%). Ceramics and cement chemistry (C04B) sits lower at 13.4%, and dentistry-specific applications (A61C) are the smallest major category at 3.9%. Since individual records often carry multiple IPC classes, these percentages overlap rather than summing to 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Bone Graft Substitutes covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.